Abstract 772P
Background
Granulosa cell tumor is a malignant neoplasm that arises from the ovarian sex-cord stromal cell. Surgery is the primary treatment. Recurrence ratios are high in patients who had stage IC or over. In this study, we aimed to assess the efficacy of hormonal therapy in pretreated patients with metastatic or refractory ovary granulosa cell tumors.
Methods
We retrospectively evaluated the clinicopathological and treatment features of patients who received hormonal therapy. Survival analyses were performed with Kaplan-Meier and Cox regression method.
Results
Thirteen patients were included in the study. The median age was 49 (range, 34-61) years. The number of median surgery was 3 (range, 2-8) since at diagnosis. All patients had stage I (84.6%) or stage II (15.4%) disease at diagnosis. Twelve (92.3%) patients had received at least one chemotherapy regimen. Ten (76.9%) of the patients had at least two metastatic sites. Intraabdominal metastasis was detected in 12 (92.3%) patients. Two (15.4%) patients had lung metastasis. Before hormonal therapy, inhibin levels were high in 81.2% of the patients. The patients received different hormonal agents (LHRH + aromatase inhibitor-three patients, LHRH + tamoxifen -six patients, aromatase inhibitors- three patients, tamoxifen-one patients). Median progression-free survival was 17.7 (CI 95%, 14.7-20.6) months. Overall response (complete or partial) was detected in 33.3% of the patients, Stable response was observed in 66.7% of the patients. Also, inhibin levels decreased in 88.9% of the patients. After disease progression with hormonal therapy, the patients were treated with surgery (53.8%), received chemotherapy (76.9%), and second-line hormonotherapy (46.2%).
Conclusions
This study showed that hormonal therapy is effective in pretreated patients with refractory or metastatic ovary granulosa cell tumors. Despite the patients' small number and treatment heterogeneity, disease control was provided in all patients. Also, inhibin levels correlated with the response to treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.